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Abstract
Background: p75NTR has been used to isolate esophageal and corneal epithelial stem cells. In the
present study, we investigated the expression of p75NTR in esophageal squamous cell carcinoma
(ESCC) and explored the biological properties of p75NTR+ cells.
Methods:  p75NTR expression in ESCC was assessed by immunohistochemistry. p75NTR+ and
p75NTR-  cells of 4 ESCC cell lines were separated by fluorescence-activated cell sorting.
Differentially expressed genes between p75NTR+ and p75NTR- cells were determined by real-time
quantitative reverse transcription-PCR. Sphere formation assay, DDP sensitivity assay, 64copper
accumulation assay and tumorigenicity analysis were performed to determine the capacity of self-
renewal, chemotherapy resistance and tumorigenicity of p75NTR+ cells.
Results: In ESCC specimens, p75NTR was found mainly confined to immature cells and absent in
cells undergoing terminal differentiation. The percentage of p75NTR+ cells was 1.6%–3.7% in Eca109
and 3 newly established ESCC cell lines. The expression of Bmi-1, which is associated with self-
renewal of stem cells, was significantly higher in p75NTR+ cells. p63, a marker identified in
keratinocyte stem cells, was confined mainly to p75NTR+ cells. The expression of CTR1, which is
associated with cisplatin (DDP)-resistance, was significantly decreased in p75NTR+ cells. Expression
levels of differentiation markers, such as involucrin, cytokeratin 13, β1-integrin and β4-integrin,
were lower in p75NTR+ cells. In addition, p75NTR+ cells generated both p75NTR+ and p75NTR- cells,
and formed nonadherent spherical clusters in serum-free medium supplemented with growth
factors. Furthermore, p75NTR+ cells were found to be more resistant to DDP and exhibited lower
64copper accumulation than p75NTR- cells.
Conclusion: Our results demonstrated that p75NTR+ cells possess some characteristics of CSCs,
namely, self-renewal and chemotherapy resistance. Chemotherapy resistance of p75NTR+ cells may
probably be attributable to decreased expression of CTR1.
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Background
The "cancer stem cell" theory has aroused increasing inter-
est in the field of oncology [1-4]. According to this theory,
cancer stem cells (CSCs), which account for a very small
proportion of tumor tissue, have the self-renewal property
typical of normal stem cells. CSCs rarely divide, but they
are able to produce fast-proliferating daughter cells. Previ-
ous studies have demonstrated the existence of CSCs in a
variety of tumors including liver carcinoma [5,6], brain
tumors [1,2], breast carcinoma [7], lung carcinoma [8],
colorectal carcinoma [9], pancreatic carcinoma [10], and
thyroid tumors [11]. In addition to the basic stem cell
properties, CSCs also display high resistance to radiation
and conventional chemotherapy. Bao et al [12] reported
that CD133 positive CSCs contributed to glioma radiore-
sistance through preferential activation of DNA damage
checkpoint response and increased capacity of DNA
repair. Liu et al [13] also reported that CD133 positive
CSCs in brain glioblastoma showed strong chemoresist-
ance attributable to higher expression of ABCG2 and
MGMT. These studies strongly support the cancer stem
cell theory that CSCs are the underlying cause of recur-
rence and metastasis of tumors.
Low-affinity neurotrophin receptor (p75NTR), a member
of tumor necrosis factor superfamily [14,15], has been
shown to paradoxically mediate neuronal survival and
differentiation or apoptotic cell death, depending on the
environment of the cells [16]. Okumura et al [17]
reported that p75NTR+  esophageal epithelial cells were
stem cells due to their capacity of proliferation, self-
renewal and multidirectional differentiation. p75NTR was
also used for screening mouse testis peritubular smooth
muscle precursors [18], rat fat multipotential stem cells
[19], and human corneal epithelial progenitor cells [20].
In the present study, we found that p75NTR+ esophageal
squamous cell carcinomas (ESCC) cells exhibited proper-
ties of CSCs in terms of self-renewal and chemotherapy
resistance.
Methods
ESCC specimens and immunohistochemistry
A total of 100 patients with histopathologically confirmed
ESCC who underwent surgery at Changhai Hospital
between 2005 and 2006 were selected. Informed consent
was obtained from the patients or their guardians. No pre-
operative history of radio-therapy or chemotherapy was
reported in any of the patients.
Antibodies used in this study included: mouse anti
human p75NTR (Upstate Corporation, USA), involucrin
(Santa cruz Corporation, USA), p63 (DAKO Corporation,
Denmark) and ki-67 (DAKO Corporation, Denmark). For
antigen retrieval, the slides were treated with boiling 10
mM citrate buffer (pH 6.0) for 25 min. Immunohisto-
chemical staining was performed using EnVision™ Kit
(HRP, DAKO Corporation, Denmark). All slides were
evaluated independently by two investigators (XHL. and
CGB.) without prior knowledge of the clinical informa-
tion of the patients. The samples were divided into two
groups according to the percentage of p75NTR staining-
positive cells, tumors were classified as positive if >10%
tumor cells were stained and negative if ≤ 10% tumor cells
were stained[21]. The ki-67 index was defined as the per-
centage of ki-67 positive tumor cell nuclei.
Cell source and culture condition
Esophageal carcinoma cell line Eca109 was purchased
from Shanghai Cell Biology Institute of the Chinese Acad-
emy of Sciences. Eca109-eGFP was established by lentivi-
ral vector (Invitrogen Corporation, USA). Cells were
cultured in DMEM containing 10% fetal bovine serum at
37°C, 5% CO2. Three cell lines (SHEC-1, SHEC-4 and
SHEC-5) were newly established. In brief, surgically
removed fresh specimens were rinsed with serum-free
RPMI-1640 (Invitrogen Corporation, USA) for 3 times,
cut into 1 mm3 tissue masses and incubated in enzymatic
dissociation in DMEM containing 1 mg/mL collagenase
IV (Invitrogen Corporation, USA) for 4–6 h at 37°C. The
isolated cells were cultured in DMEM containing 10%
fetal bovine serum in a humidified 5% CO2 atmosphere at
37°C. Three cell lines were established by serial passage
and designated SHEC-1, SHEC-4 and SHEC-5, respec-
tively.
Flow cytometry and fluorescence-activated cell sorting
Tumor cells were harvested and adjusted to a concentra-
tion of 1 × 106 cells/ml with Buffer1 (phosphate buffered
saline containing 0.5% bovine serum albumin and 2 mM
EDTA). The cells were incubated with primary antibody
for 2 h at 4°C. After washing with Buffer1 twice, the cells
were resuspended in 500 μl Buffer1, to which PE-conju-
gated goat anti mouse IgG (BD PharMingen Corporation,
USA) was added. The samples were then incubated away
from light for 15 min at 4°C. Following staining, the sam-
ples were analyzed using a FACSCalibur flow cytometer
and CellQuest software (BD Biosciences, San Jose, CA).
Primary antibodies were: mouse anti human p75NTR,
involucrin,  β1-integrin (Santa cruz Corporation, USA)
and cytokeratin 13 (Santa cruz Corporation, USA). Fluo-
rescence-activated cell sorting (FACS) of p75NTR+and
p75NTR-  cells was performed on a Cytomation MoFlo
cytometer (DakoCytomation Corporation, Denmark).
The top 25% most brightly stained cells were isolated as
p75NTR+ cells. Cells incubated with PE-conjugated anti-
bodies were used as controls.
RNA isolation and cDNA synthesis
Total RNA of tumor cells was extracted by RNA4PCR kit
(Amibion Corporation, USA) according to the manufac-BMC Cancer 2009, 9:9 http://www.biomedcentral.com/1471-2407/9/9
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turer's instructions. RNA was dissolved in 50 μl distilled
water containing 0.1% diethylpyrocarbonate and quanti-
tated at OD260 by spectrophotometry.
Real-time quantitative reverse transcription-PCR
Total RNA was used as the template to amplify Bmi-1,
p63, involucrin, cytokeratin 13, β1-integrin and β4-
integrin and CTR1 by real-time quantitative reverse tran-
scription-PCR (real-time qPCR). G6PDH was used as
internal control. The following primer sequences were
used, and expected product sizes were noted in parenthe-
ses.
Bmi-1: 5'-ggagaccagcaagtattgtccttttg-3' and 5'-cattgctgct-
gggcatcgtaag-3' (348 bp);
p63: 5'-cagacttgccaaatcatcc-3' and 5'-cagcattgtcagtttcttagc-
3' (120 bp);
involucrin: 5'-tcctcctccagtcaataccc-3' and 5'-gctgatccctttgt-
gtt-3' (283 bp);
cytokeratin 13: 5'-ccatgaagaggtgagcggggattg-3' and 5'-ctgt-
ggggatgggaaaggaagatgtg-3' (200 bp);
β1-integrin: 5'-gtggttgctggaattgttctta-3' and 5'-agtgttgt-
gggatttgcac-3' (219 bp);
β4-integrin: 5'-atagagtcccaggatggagga-3' and 5'-gtggtgga-
gatgctgctgta-3' (97 bp);
CTR1: 5'-aggactcaagatagcccgagaga-3' and 5'-tggtcct-
gggacaggcatgg-3' (78 bp).
G6PDH: 5'-atcgaccactacctgggcaa-3' and 5'-ttctgcatcacgtc-
ccgga-3' (191)
Sphere formation assay
Tumor cells were resuspended to 1 × 104  cells/ml in
serum-free medium (keratinocyte-SFM medium, with
addition of penicillin 100 IU/ml, streptomycin 100 μg/
ml, epidermal growth factor 5 ng/ml, bovine pituitary
extract 70 μg/ml, hydrocortisonum 0.5 μg/ml and regular
insulin 5 μg/ml in sequence). The cultures were moni-
tored for the sphere formation within 3 weeks. To passage
the spheres, medium was aspirated off and spheres were
harvested with the TransferMan NK 2 micromanipulator
(Eppendorf). After trypsin digestion, single cell suspen-
sion was prepared by mechanical dissociation. To deter-
mine the differentiation of p75NTR+ cells, single viable
floating p75NTR+ cells were collected and resuspended to 1
× 103 cells/mL in keratinocyte-SFM medium containing
10% fetal bovine serum. The expression of involucrin and
cytokeratin 13 was detected by immunocytochemistry.
DDP sensitivity assay
Stock solution of 1 mg/ml DDP (Sigma-Aldrich, USA) was
prepared in dimethylformamide and stored at -20°C for
no longer than 3 days. Isolated p75NTR+ and p75NTR- cells
were seeded into 96-well culture plates (5 × 102 cells/well)
respectively, and incubated in an atmosphere containing
5% CO2 for 24 h at 37°C. In our pilot study, DDP inhib-
ited the viability of Eca109 cells in a concentration-
dependent manner with an apparent IC10 value of 0.23
μg/ml, IC50 value of 0.47 μg/ml and IC90 value of 0.68
μg/ml. In the present study, the cells were treated with
DDP at concentration of 0.5 and 1 μg/ml based on the
pilot cytotoxicity study. MTT assay was performed to
determine the viability of the cells after they were exposed
to DDP for 4 days.
Furthermore, cell mixture composed of 10% p75NTR+
Eca109-eGFP and 90% p75NTR- Eca109 cells were cultured
for 2 days and then exposed to 0.5 and 1 μg/ml DDP for
4 days respectively. The percentage of Eca109-eGFP cells
was analyzed by flow cytometry.
64copper accumulation assay
Isolated p75NTR+ and p75NTR- cells were seeded into 6-well
culture plates (1 × 105 cells/well), and incubated in an
atmosphere containing 5% CO2 for 24 h at 37°C. The
medium was replaced with 1 ml fresh medium containing
2 μM 64CuSO4, and the cells were incubated in 5% CO2
for 0.5, 1.0, and 1.5 h at 37°C. After that, the plates were
placed on ice and rinsed 3 times with 6 ml ice-cold PBS.
Then 500 μl cell lysis buffer (0.1% Triton X-100 and 1%
SDS in PBS) was added to the wells and the lysate was har-
vested by scraping the dish twice. The samples were trans-
ferred to tubes for γ counting on a Gamma 5500 B counter
(Beckman Coulter, Inc., Fullerton, CA). Samples unex-
posed to 64CuSO4 were measured as control.
Xenograft tumorigenicity assay
Six to eight-week-old female congenitally immune-defi-
cient nonobese diabetic/severe combined immune-defi-
ciency (NOD/SCID) mice were randomly divided into
different groups and maintained under standard condi-
tions according to the institution's guidelines. Various
numbers of p75NTR+ and p75NTR- Eca109 cells were sus-
pended in 200 μl serum-free DMEM or in 200 μl serum-
free DMEM/Matrigel (1:1), and injected subcutaneously
into NOD/SCID mice. The mice were killed 10–16 weeks
after tumor cell inoculation. Animals with no signs of
tumor burden were further examined by autopsy to con-
firm that there was no tumor development.
Statistical analysis
For comparisons of gender, necrosis, distant metastasis
and paraesophageal lymph node metastasis betweenBMC Cancer 2009, 9:9 http://www.biomedcentral.com/1471-2407/9/9
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p75NTR positive and negative groups, chi-square test was
performed. The correlation between p75NTR expression
and pathological grade was analyzed by Cochran-Mantel-
Haenszel Statistics. Age of the patients and tumor diame-
ter between two groups was compared by independent
Student's t test. Other data obtained from experiments
were expressed as mean ± SD (  ± s) and tested by Stu-
dent's t test. Statistical analyses were conducted with SAS
Statistical Software (version 9.1.3). P < 0.05 was consid-
ered significant.
Results
Expression of p75NTR in ESCC specimens
As shown in Figure 1A, p75NTR was found on the mem-
brane of the basal cells in normal esophageal epithelium
(NEE) and absent in the spinous layer. In well differenti-
ated cases (WDC) and moderately differentiated cases
(MDC), p75NTR staining was apparent in the first few lay-
ers adjacent to the infiltrative margin of the tumors. In
contrast, in poorly differentiated cases (PDC), p75NTR was
diffusely distributed.
In contrast to p75NTR, involucrin staining was located in
the spinous layer of NEE. Parallel sections from WDC and
x
Parallel sections from normal esophageal epithelial and ESCC specimen Figure 1
Parallel sections from normal esophageal epithelial and ESCC specimen. (A) In NEE, p75NTR was located mainly in 
the basal layer; in WDC, p75NTR positive staining was apparent in the first one to two layers from the infiltrative margin, areas 
exhibiting stratified squamous pearl formation were negative for p75NTR; in MDC, p75NTR was expressed in wider range from 
the margin of the tumors; p75NTR was diffusely distributed in PDC.(B) In NEE, basal cells coexpressed p75NTR and p63, and very 
few p75NTR+ cells expressed ki-67; in WDC and MDC, p75NTR+ cells were at some distance surrounding involucrin+cells where 
most of the cells were coexpressed p63, and a small proportion of p75NTR+ cells expressed ki-67; in PDC, few cells were posi-
tive for involucrin, more cells contained both p63 and p75NTR, and their distribution was chaotic, a large number of p75NTR+ 
cells stained brightly for ki-67. (Bars = 200 μm)BMC Cancer 2009, 9:9 http://www.biomedcentral.com/1471-2407/9/9
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MDC showed that p75NTR+ cells were located at some dis-
tance from the terminally differentiated cells stained
brightly for involucrin, and generally absent in the zones
immediately surrounding the involucrin+ cells. In PDC,
there were few cells positive for involucrin, most of the
cells were stained very brightly for p75NTR. Distribution of
the p75NTR+ cells was irregular. In NEE, only a small pro-
portion of p75NTR+ cells expressed ki-67. In ESCC speci-
mens, however, the proportion of p75NTR  and ki-67
coexpressing cells increased. In addition, p75NTR and p63
had similar tissue distribution both in NEE and in ESCC
specimens (Figure 1B).
The correlation between p75NTR expression and various
prognostic factors were investigated (Table 1). p75NTR
expression correlated with age (P = 0.008), tumor diame-
ter (P = 0.004) and pathological grade (P = 0.001). There
was no significant correlation between p75NTR expression
and other factors such as gender, ki-67 index, necrosis,
distant metastasis and paraesophageal lymph node
metastasis.
Growth characteristics of p75NTR+ cells
As shown in Figure 2 A~D, p75NTR+ cells were detected in
all 4 ESCC cell lines. The percentage of p75NTR+ cells in
Eca109, SHEC-1, SHEC-4 and SHEC-5 was 2.5%, 1.6%,
1.9% and 3.7%, respectively. To compare the growth char-
acteristics of p75NTR+ and p75NTR- cells, equal numbers of
sorted cells were cultured in vitro for up to 6 weeks. The
percentage of p75NTR+ cells decreased progressively during
the first three weeks and maintained steady thereafter. The
cells derived from p75NTR+ cells contained both p75NTR+
and p75NTR- cells, whereas those from p75NTR- cells gener-
ated only p75NTR- cells.
In addition, the results of phenotypic analysis showed
p75NTR+ cells of different passages (total passages = 30)
generated p75NTR+β1-integrin-, p75NTR-β1-integrin-  and
p75NTR-β1-integrin+  progenies (Figure 2E), whereas
p75NTR- cells generated only p75NTR- cells even in the 30th
passage (Figure 2F).
Molecular characteristic of p75NTR+ cells
As compared to p75NTR- cells, p75NTR+ cells were shown to
differentially express the following genes (Figure 3 A~G):
(a) p63, a marker identified in keratinocyte stem cells
[22], was confined mainly to p75NTR+ cells; (b) Bmi-1, a
transcription repressor implicated in the regulation of
self-renewal of normal and malignant stem cells [7,23],
was significantly higher in p75NTR+ cells; (c) copper trans-
porter 1 gene (CTR1) [24], a specific transporter of copper
associated with DDP resistance, was confined mainly to
p75NTR- cells. In addition, p75NTR+ cells expressed lower
levels of markers of differentiation such as involucrin,
cytokeratin 13, β1-integrin and β4-integrin than p75NTR-
cells.
Sphere-forming capacity of p75NTR+ cells
Tumor cells were cultured in serum-free medium supple-
mented with growth factors. The formation of spheres
were observed 10–15 days later. The percentage of
p75NTR+ cells was 68.3%, which was significantly higher
than thatcultured in DMEM containg 10% FBS. Similar
results were also obtained from SHEC-1 (62.7%), SHEC-
4 (58.5%) and SHEC-5 (74.2%) (Figure 4A).
Table 1: Relationship between p75NTR expression and clinicopathologic characteristics
clinical factors squamous cell carcinomas
p75NTR-positive p75NTR-negative test P
Total 62 38
age (year) 62.95 ± 9.27 58.13 ± 7.524 2.71 0.008
gender
Male 47/62 (75.8%) 9/38 (23.7%) 0.32 0.569
Female 15/62 (24.2%) 29/38 (76.3%)
tumor diameter (cm) 5.38 ± 1.76 4.16 ± 1.85 3.30 0.001
KI
high 40/62 (64.5%) 24/38 (63.2%) 0.02 0.891
Low 22/62 (35.5%) 14/38 (36.8%)
necrosis 17/62 (27.4%) 14/38 (36.8%) 0.98 0.323
*distant metastasis 16/62 (25.8%) 10/38 (26.3%) 0.00 0.955
Para-esophageal lymph node metastasis 29/62 (46.8%) 19/38 (50.0%) 0.10 0.754
pathological grade
poorly differentiated 6 (9.7%) 10 (26.3%) 11.78 0.001
moderately differentiated 26 (41.9%) 22 (57.9%)
well differentiated 30 (48.4%) 6 (15.8%)
* Distant metastasis involved supraclavicular lymph node, abdominal lymph node, liver, lung, trachea and subcutaneous of the back.BMC Cancer 2009, 9:9 http://www.biomedcentral.com/1471-2407/9/9
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p75NTR expression in ESCC cell line Figure 2
p75NTR expression in ESCC cell line. p75NTR+ cells made up 2.5% in Eca109 (A), 1.6% in SHEC-1 (B), 1.9% in SHEC-4 (C) 
and 3.7% (D) in SHEC-5. Cells derived from p75NTR+ cells contained both p75NTR+ and p75NTR- cells, whereas those from 
p75NTR- cells generated only p75NTR- cells. In p75NTR+ subpopulation, the percentage of p75NTR+ cells declined time-depend-
ently. In addition, p75NTR+ cells could be serial passaged and generated p75NTR+ β1-integrin-, p75NTR- β1-integrin-and p75NTR- 
β1-integrin+ progenies (E), whereas p75NTR- cells generated only p75NTR- cells in 5th passage (F).BMC Cancer 2009, 9:9 http://www.biomedcentral.com/1471-2407/9/9
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Different gene mRNA expression in p75NTR+ and p75NTR- subpopulation Figure 3
Different gene mRNA expression in p75NTR+ and p75NTR- subpopulation. mRNA expression level was measured by 
real-time qPCR. p63 (A) and Bmi-1 (B) were more intensely expressed in p75NTR+ cells compared with p75NTR- cells. Con-
versely, CTR1 (C), involucrin (D), cytokeratin 13 (E), β1-integrin (F) and β4-integrin (G) expression were lower.BMC Cancer 2009, 9:9 http://www.biomedcentral.com/1471-2407/9/9
Page 8 of 12
(page number not for citation purposes)
Sphere formation in serum-free medium Figure 4
Sphere formation in serum-free medium. Tumor Cells formed nonadherent spheres in serum-free medium. The per-
centage of p75NTR+ cells increased to 68.3% in Eca109, 62.7% in SHEC-1, 58.5% in SHEC-4 and 74.2% in SHEC-5 (A). Single 
p75NTR+ cell could proliferate in serum-free culture and formed nonadherent cells sphere (B), contained both p75NTR+ and 
p75NTR- cells (C); p75NTR+cells obtained from the spheres did not expressed differentiated markers involucrin (D) and cytoker-
atin 13 (E). Floating p75NTR+cells could adhere and expressed involucrin (F) and cytokeratin 13 (G) in DMEM containing 10% 
fetal bovine serum. In addition, p75NTR+ cells could be expanded as floating cell spheres for more than 30 passages, and the per-
centage of p75NTR+ cells from passage 10, passage 20 and passage 30 was 66.4%, 56.3% and 59.2%, respectively (H). B and H 
bars = 100 μm. (F and G, bars = 50 μm)BMC Cancer 2009, 9:9 http://www.biomedcentral.com/1471-2407/9/9
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Sphere-forming capacity of p75NTR+ cells isolated from
Eca109 was examined. As shown in Figure 4B, single
p75NTR+ cell could proliferate in the serum-free medium.
Three to 6 days after plating, the formation of spheres
were observed. Two weeks later, the size of cell spheres
became relatively large with the average diameter of 400
μm. Flow cytometry showed that the spheres contained
both p75NTR+ and p75NTR- cells (Figure 4C). Meanwhile,
p75NTR+  cells obtained from spheres did not expresse
mature markers involucrin (Figure 4D) and cytokeratin 13
(Figure 4E). Under differentiating condition (10% fetal
bovine serum supplementation), the floating p75NTR+
cells could adhere to the dish and form a single layer of
confluent cells expressing involucrin (Figure 4F) and
cytokeratin 13 (Figure 4G). Furthermore, p75NTR+ cells
from these spheres were able to passage repeatedly and
the percentage of p75NTR+ cells from passage 10, passage
20 and passage 30 was 66.4%, 56.3% and 59.2%, respec-
tively (Figure 4H). In contrast, p75NTR- cells were not able
to form spheres.
DDP sensitivity and 64copper accumulation assays
Cell viability was measured by MTT assay 4 days after sub-
jecting p75NTR+ and p75NTR- cells to DDP. The OD570 val-
ues of p75NTR+ cells were 0.34 ± 0.06 (0 μg/ml, n = 3), 0.27
± 0.08 (0.5 μg/ml, n = 3) and 0.19 ± 0.05 (1 μg/ml, n = 3),
whereas the values of p75NTR- cells were 0.36 ± 0.04 (0 μg/
ml, n = 3), 0.16 ± 0.06 (0.5 μg/ml, n = 3) and 0.03 ± 0.03
(1 μg/ml, n = 3). These results suggested that the viability
of p75NTR- cells decreased significantly as compared to that
of p75NTR+ cells (P < 0.05, Figure 5A).
The DDP resistance of p75NTR+ cells was further examined
by detecting enrichment of eGFP labeled p75NTR+ cells co-
cultured with p75NTR- cells following exposure to DDP. It
was demonstrated that DDP induced significant enrich-
ment of p75NTR+ cells and their percentage increased from
9.4% to 48.1% and 86.2%, respectively (Figure 5B).
64copper accumulation assay of the p75NTR+ and p75NTR-
cells was performed. The 64copper accumulation value of
p75NTR+ cells were 43.6 ± 12.0 pmol Cu/mg protein (0.5
h, n = 3), 120.7 ± 29.3 pmol Cu/mg protein (1 h, n = 3)
and 208.6 ± 40.5 pmol Cu/mg protein (1.5 h, n = 3),
whereas the values of p75NTR- cells were 193.4 ± 49.1 (0.5
h, n = 3), 457.4 ± 87.7 (1 h, n = 3) and 658.2 ± 98.2 (1.5
h, n = 3). The result showed that 64copper accumulation
in p75NTR+  cells was significantly lower than that in
DDP resistance of p75NTR+ cells Figure 5
DDP resistance of p75NTR+ cells. Treated with 0.5 and 1 μg/ml DDP for 4 days, the number of viable cells in p75NTR+sub-
population was significant higher than that in p75NTR- subpopulation. (B) Enrichment assay showed that the fraction of eGFP-
carrying cells derived from p75NTR+ cells increased from 9.4% to 48.1% and 86.2%, respectively. (C) Copper accumulation was 
less in the p75NTR+ cells than in the p75NTR- cells at each time point. (B, bars = 100 μm)BMC Cancer 2009, 9:9 http://www.biomedcentral.com/1471-2407/9/9
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p75NTR- cells at each time point (P < 0.05 for all compari-
sons).
Xenograft tumorigenicity assay
Various numbers of sorted Eca109 cells were suspended in
200 μl serum-free DMEM and injected subcutaneously
into NOD/SCID mice. The results showed that at least 2 ×
103 p75NTR+ cells or p75NTR- cells were needed to generate
tumors. When transplanted cells were suspended in
DMEM/Matrigel, the result showed that the lowest
number of p75NTR+ and p75NTR- cells to generate tumors
was 500 and 2 × 103, respectively (Table 2).
Discussion
In the present study, we found that p75NTR was confined
to immature cells and absent in cells undergoing terminal
differentiation in ESCC specimens. We also found the per-
centages of p75NTR+ cells in the 4 ESCC cells lines ranged
from 1.13% to 3.35%, which was similar to the percent-
ages of CSCs as previously reported [1,25,26].
In agreement with the previous report [21], p75NTR was
confined to the basal layer in NEE. Although statistical
analysis showed that positive rate of p75NTR was not asso-
ciated with lower pathological grade, histopathological
analysis indicated that the number and distribution of
p75NTR+ cells altered depending on the degree of anaplasia
in ESCC. In WDC, p75NTR was confined to the surround-
ing basal-like cells which were at some distance from the
centers of terminal differentiation. In MDC, the number
of p75NTR+ cells increased and their distribution became
irregular with respect to the centers of terminal differenti-
ation. In PDC, p75NTR was diffusely distributed and there
was virtually no relation between the distribution of
p75NTR+ cells and the small zones of terminal differentia-
tion. Thus, both in NEE and ESCC, p75NTR was mainly
expressed in immature cells. Ki-67, a cell proliferation-
associated nuclear antigen, was found in all stages of the
cell cycle. Immunostaining for p75NTR and ki-67 revealed
that only a small proportion of p75NTR+cells expressed ki-
67 in NEE, while the number of cancer cells coexpressing
p75NTR and ki-67 increased in ESCC. These results sug-
gested that p75NTR was expressed in cells that were prolif-
erating or capable of proliferating. Furthermore, the
distribution of p75NTR in ESCC was similar to that of p63,
a marker identified in keratinocyte stem cells [27,28].
Taken together, it could be deduced that p75NTR  was
expressed in undifferentiated cells. Toinvestigate the iden-
tity of p75NTR+ cells as CSCs in ESCC, we further studied
the biological characteristics of p75NTR+ cells in Eca109
and 3 newly established cell lines.
Self-renewal capacity of p75NTR+ cells
Self-renewal is one of the hallmarks of CSCs, which refers
to the ability to form new stem cells with identical, and
intact potential for proliferation, expansion, and differen-
tiation. In the present study, our results revealed that
p75NTR+ cells could generate both p75NTR+ and p75NTR-
progenies, but p75NTR- cells could generate only p75NTR-
cells, suggesting a p75NTR-associated cell hierarchy may
exist in ESCC.
Sphere-forming ability in serum-free medium was used to
reflect the self-renewal capacity of CSCs in a variety of
studies and sphere cells were widely regarded as CSCs
[7,29-32]. In the present study, we found ESCC cells could
form cell spheres and the percentage of p75NTR+ cells
increased significantly. p75NTR+ cells could be propagated
undifferentiatedly cells in serum-free medium and differ-
entiate into involucrin+ and cytokeratin 13+ cells under
differentiating conditions.
The higher expression of self-renewal associated gene and
lower expression of differentiation markers also suggested
that p75NTR+ cells possessed the characteristics of ESCC
CSCs.
Chemotherapy resistance of p75NTR+ cells
DDP is an important chemotherapeutic agent for human
esophageal carcinoma though resistance to it is likely to
develop during the therapy [33]. Reduced DDP accumula-
tion is considered as the most important feature[34,35].
DDP enters cells much more slowly than most other
classes of small-molecule anticancer agents. Current evi-
dences showed that DDP uptake is mediated by CTR1, a
major copper influx transporter in mammalian cells.
Accumulated evidence indicates that CTR1 accountes for
Table 2: Tumorigenicity of p75NTR+ ESCC in NOD/SCID mice xenograft
Cell numbers injected per mouse DMEM DMEM/Matrigel (1:1)
p75NTR+ p75NTR- p75NTR+ p75NTR-
100 0/6 0/6 0/6 0/6
500 0/6 0/6 2/6 0/6
2,000 2/6 1/6 3/6 2/6
10,000 4/6 4/6 5/6 4/6
100,000 6/6 5/6 6/6 6/6BMC Cancer 2009, 9:9 http://www.biomedcentral.com/1471-2407/9/9
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DDP uptake of cells in kinds of cancers including ovarian
carcinoma, small-cell lung cancer, and prostate cancer.
The lower expression of CTR1 indicated p75NTR+ cells
might be more resistant to DDP than p75NTR- cells. In
addition, we used 64copper accumulation experiment to
elucidate the DDP resistance because of the similar mech-
anism of DDP and copper uptake [36,37]. The lower
64copper accumulation also suggested that the low expres-
sion of CTR1 markedly impaired the influx of DDP in
p75NTR+ cells.
Meanwhile, the result of MTT assay showed that p75NTR+
cells were more resistant to DDP than p75NTR- cells in all
4 esophageal carcinoma cell lines. Furthermore, the result
of the enrichment assay offered the direct evidence that
p75NTR+ cells were more resistant to DDP since p75NTR+
and p75NTR- cells were cocultured in the same condition.
Xenograft tumorigenicity of p75NTR+ 
Finally, we injected 102 to 105 p75NTR+ and p75NTR-cells
isolated from Eca109 into NOD/SCID mice to determine
whether p75NTR+ cells possess higher tumorigenicity in
immunocompromised mice than p75NTR- cells. Although
tumors were generated at similar cell doses (more than 2
× 103) when p75NTR+ cells or p75NTR- cells were suspended
in DMEM, higher tumorigenicity was shown by p75NTR+
cells when the transplanted cells were suspended in
DMEM/Matrigel before inoculation. The results con-
firmed the tumorigenicity of p75NTR+  cells  in vivo.
Although p75NTR- cells also exhibited some tumorigenic
potential, this may be due to the meta-topical implanta-
tion of cells into a more permissive environment (e.g. sub-
cutaneous site) compared to the environment of origin.
Conclusion
In summary, we found that (1) p75NTR was mainly con-
fined to immature cells capable of proliferation and
absent from cells which were undergoing terminal differ-
entiation in ESCC. (2) p75NTR+ cells isolated from ESCC
cell lines were able to generate both p75NTR+ and p75NTR-
cells, to form spheres in serum-free medium supple-
mented with growth factors, and to differentiate into
mature esophageal squamous epithelial cells. and (3)
p75NTR+ cells were more resistant to DDP than p75NTR-
cells. Our results demonstrated that p75NTR+ cells pos-
sessed some characteristics of CSCs, namely, self-renewal
and chemotherapy resistance.
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